Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study
Inhibrx Biosciences, Inc. (NASDAQ:INBX) is one of the best small cap stocks to buy for 10x potential. Inhibrx Biosciences, Inc.
Inhibrx Biosciences Inc. (INBX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 62,201 | $5,893,545 | +24% | 0.01% |
| 2. | Quantinno Capital Hoon Kim | 17,396 | $1,648,271 | -2% | 0% |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 8,800 | $833,801 | -58% | 0% |
| 4. | Platinum Asset Management Kerr Neilson | 6,146 | $582,334 | 0.14% | |
| 5. | Centiva Capital Karim Abbadi And Edward Mcbride | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.19 | 18,750 | $266,101.88 | 69,843 | 2024-11-20 | Filing | |
| $14.19 | 18,750 | $266,101.88 | 69,843 | 2024-11-20 | Filing | |
| $14.23 | 34,843 | $495,707.88 | 51,093 | 2024-11-19 | Filing | |
| $14.23 | 34,843 | $495,707.88 | 51,093 | 2024-11-19 | Filing | |
| $15.00 | 6,667 | $100,005.00 | 20,443 | 2024-10-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.25 | 25,042 | $807,604.50 | 102,864 | 2025-10-07 | Filing | |
| $32.25 | 16,315 | $526,158.75 | 67,018 | 2025-10-07 | Filing | |
| $32.25 | 308,643 | $9,953,736.75 | 1,267,823 | 2025-10-07 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,308,051 | $123,937,898 | 0.01% | |
| 2. | 1,157,926 | $109,713,489 | 20.54% | |
| 3. | 870,551 | $82,484,676 | 0.08% | |
| 4. | 825,972 | $78,260,825 | 0% | |
| 5. | 640,458 | $60,683,396 | 0% |
News See All
15 Best Small Cap Stocks to Buy for 10x Potential
On May 11, Dan Niles, Niles Investment Management founder, appeared on CNBC’s ‘The Exchange’ to talk about his view on equity markets while conducting a comparison with the prior periods.
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts
Inhibrx Biosciences Inc. (NASDAQ:INBX) is one of the best emerging technology stocks to invest in.
12 Best Emerging Technology Stocks to Invest In
On December 24, Kevin Simpson of Capital Wealth Planning joined 'Closing Bell' on CNBC to talk about AI tailwinds and the diverging tech picture.
Inhibrx Biosciences Advances HexAgon-HN Study for Head, Neck Cancer
Inhibrx Biosciences Inc. (NASDAQ:INBX) is one of the most profitable new stocks to buy now.
10 Most Profitable New Stocks to Buy Now
Earlier on July 1, Ralph Schlosstein, Evercore's chairman emeritus and BlackRock's co-founder, joined 'Closing Bell Overtime' on CNBC to talk about his outlook for markets heading into H2 2025.
Hedge Fund and Insider Trading News: Steve Cohen, Cathie Wood, Caledonia Investments, Vapotherm Inc (VAPO), Inhibrx, Inc. (INBX), and More
The cryptocurrency industry eagerly awaits the next decision from the Securities and Exchange Commission after a U.S. court ruling a week ago regarding Grayscale Investments (GBTC).
12 Best High Risk High Reward Stocks To Buy Now
In this piece, we will take a look at the 12 best high risk high reward stocks to buy now.
Should You Hold Inhibrx (INBX)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.
5 Best Stocks Under $20 According to Billionaire Andreas Halvorsen's Viking Global
In this piece, we will take a look at the top five best stocks to buy under $20 according to billionaire Andreas Halvorsen's Viking Global.